I have overseen over 20 phase III clinical trials. Many of those clinical trials have failed to show statistical efficacy. In every single one of those trials there are patients who see dramatic and undeniable benefits. In the oncology field, we continue to treat such patients even when the statistics say, no benefit. And, sometimes those patients just stay better. My point is, when the trial shows "no better than placebo", it doesn't mean the treatment doesn't work. It might be that. But more likely it means we don't know how to define the population of folks for whom the treatment does work. Maybe it's a particular genetic background, maybe it's age, gender, serum CPR or Tau level. Maybe it's something else. This stuff is complicated and interesting. And we are still figuring it out.